For research and educational purposes only. Not medical advice.
TB-500 Reference
Educational, not medical advice reference for TB-500: Recovery; regulatory status, evidence posture, source review, and schedule notes. Also kno…
Reference summary
Evidence is mostly extrapolated from thymosin beta-4 animal literature on tissue repair and myocardial injury. Human TB-500-specific clinical evidence is not established.
Regulatory and posture
- Categories
- Recovery
- Aliases
- Thymosin beta-4 fragment, TB4 fragment
- Evidence posture
- preclinical - Commercial claims lean heavily on thymosin beta-4 extrapolation, not direct human TB-500 trials.
- Regulatory status
- No FDA-approved TB-500 drug label. Published literature more often studies full-length thymosin beta-4 than commercial TB-500 vials, so exact product identity matters.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed: thymosin beta 4 myocardial-injury mouse study
- PubMed: thymosin beta 4 post-MI caution study
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.